MyriadHealth

Myriad Genetics is a leading molecular diagnostics and precision medicine company that develops and commercializes genetic tests to assess disease risk and guide treatment decisions. The company is best known for its pioneering work in identifying the BRCA1 and BRCA2 genes and launching the first commercial tests for hereditary breast and ovarian cancer. Myriad's current portfolio includes the MyRisk Hereditary Cancer test, the GeneSight psychotropic test for mental health, and the Prolaris prognostic test for prostate cancer. By integrating genomic data with clinical insights, Myriad provides actionable information to healthcare providers and patients across oncology, urology, women's health, and mental health specialties.